Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system

Human Reproduction

Volumn 25, Issue 5, 2010, Pages 1158-1164

  Bahamondes, M Valeria ^a   Monteiro, Ilza ^a   Castro, Sara ^a   Espejo Arce, Ximena ^a   Bahamondes, Luis ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Bone mineral density; Contraception; Levonorgestrel releasing intrauterine system; Mirena

Indexed keywords

ESTRADIOL; LEVONORGESTREL;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; BONE DENSITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; ETHNICITY; FEMALE; FOREARM; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PREGNANCY; PROSPECTIVE STUDY; RADIUS; ULNA;

EID: 77951107084     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq043     Document Type: Article

References (37)

1. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735.
2. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, Diaz J, Faúndes A. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 2000;62:23-27.
3. Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X, Monteiro-Dantas C. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J Reprod Med 2003;48:637-640.
4. Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod 2006a;21:1316-1319.
5. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, Petta CA. A prospective study of the forearm bone density of users of etonorgestrel-and levonorgestrel-releasing contraceptive implants. Hum Reprod 2006b; 21:466-470.
6. Bahamondes L, Bahamondes MV, Monteiro I. Levonorgestrel-releasing intrauterine system: uses and controversies. Expert Rev Med Devices 2008;5:437-445.
7. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004;103:899-906.
8. Consensus Development Conference, 1993. Consensus Development Conference, diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-650.
9. d'Arcangues C. WHO statement on hormonal contraception and bone health. Contraception 2006;73:443-444.
10. Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo MM, Arce XE. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 2000; 62:59-61.
11. Enŕquez J, Lemus AE, Chimal-Monroy J, Arzate H, Garća GA, Herrero B, Larrea F, Pérez-Palacios G. The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites. J Endocrinol 2007;193;:493-504.
12. Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L, Francoeur D, Gilbert A, Gilbert F, Roy G et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception 2009;79:167-177.
13. Gur A, Nas K, Cevik R, Sarac AJ, Ataoglu S, Karakoc M. Influence of number of pregnancies on bone mineral density in postmenopausal women of different age groups. J Bone Miner Metab 2003;21:234-241. (Pubitemid 41184290)
14. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65:129-132. (Pubitemid 34258502)
15. Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 2009;80:84-89.
16. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. J Am Med Assoc 2004;291:1456-1463. (Pubitemid 38543736)
17. Jones T, Davie MW. Bone mineral density at distal forearm can identify patients with osteoporosis at spine or femoral neck. Br J Rheumatol 1998;37:539-543.
18. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104-1116.
19. Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 2005;192:1316-1324.
20. Luukkainen T, Toivonen J. Levonorgestrel-releasing intrauterine IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-276.
21. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254-1259.
22. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception 2002;65:325-328.
23. Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF, Fernandes AM, Monteiro I, Bahamondes L. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel-and levonorgestrel-releasing contraceptive implants. Reprod Health 2007;12:11.
24. Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;52:35-39.
25. Paton LM, Alexander JL, Nowson CA, Margerison C, Frame MG, Kaymakci B, Wark JD. Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study. Am J Clin Nutr 2003;77:707-714.
26. Petitti DB, Piaggio G, Metha S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 2000;95:736-744.
27. Picard D, Brown JP, Rosenthall L, Couturier M, Lévesque J, Dumont M, Ste-Marie LG, Tenenhouse A, Dodin S. Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. J Clin Densitom 2004;7:111-118.
28. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-721.
29. Sarfati J, de Vernejoul MC. Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine 2009; 76:134-138.
30. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;13:581-587.
31. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri-and postmenopausal women. Contraception 2007;75:S155-S160.
32. Tamaki J, Iki M, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. Smoking among premenopausal women is associated with increased risk of low bone status: the JPOS Study. J Bone Miner Metab 2009 (in press).
33. Tang OS, Tang G, Yip PS, Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception 2000;62:161-164.
34. Volpe A, Amram A, Cagnacci A, Battaglia C. Biochemical aspects of hormonal contraceptive: effects on bone metabolism. Eur J Contracept Reprod Health Care 1997;2:123-126.
35. Wetmore CM, Ichikawa L, LaCroix AZ, Ott SM, Scholes D. Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use. Osteoporos Int 2008;19:519-527.
36. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. Geneva: WHO, 1994 (WHO technical report Series 843).
37. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 3rd edn. Geneva: WHO, 2004.